Lustosa Suzana Angelica Silva, Logullo Angela, Artigiani Ricardo, Saad Sarhan Sydney, Goldenberg Alberto, Matos Delcio
UniFOA, Centro Universitário de Volta Redonda, Rio de Janeiro, Brazil.
Acta Cir Bras. 2005 Sep-Oct;20(5):353-7. doi: 10.1590/s0102-86502005000500003. Epub 2005 Sep 5.
To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis.
This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87 years) who underwent surgery with curative intent. The mean follow-up was 28.5 months (range: 2-96 months). TNM staging, tumor recurrence, survival and cancer-related mortality were analyzed. Immunoreactivity was evaluated using DO7 (Dako) for p53 and K492 (Dako) for bcl-2. Tumors with accumulation of staining for cytoplasmic bcl-2 or nuclear p53 in more than 10% of cells were considered positive. Statistical analysis utilized Pearson chi-squared, log-rank and Wilcoxon tests, and Kaplan-Meier survival estimation (significance level: p<0.05).
p53+ was found in 11.8% (14/118), bcl-2+ in 50% (58/116) and associated p53+/bcl-2+ in 6.4% (7/109) of the tumors. There was no significant correlation between expression of these biomarkers and TNM I, II, III and IV staging (p=0.385 for p53; p=0.461 for bcl-2). For tumor recurrence, p53+ was found in 9.5% (2/21), bcl-2+ in 50% (11/22), and associated p53+/bcl-2+ in 5.2% (1/19) of the tumors (p=0.714, p=1.000 and p=0.960, respectively). For survival analysis, p53+: 57 months (45.0-68.0), bcl-2+: 78 (37.0-89.0), and p53+/bcl-2+: 62 (56.0-68.0) (p=0.319). For cancer-related mortality, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), and p53+/bcl-2+: 5.9% (2/36) of the patients (p=0.432, p=0.688 and p=0.907, respectively).
No correlation was found between tumor expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal adenocarcinoma.
分析p53和bcl-2表达与结直肠癌分期及预后之间的相关性。
这是一项回顾性研究，纳入了125例接受根治性手术的结直肠癌患者（67例女性和58例男性；年龄30 - 87岁）。平均随访时间为28.5个月（范围：2 - 96个月）。分析TNM分期、肿瘤复发、生存率和癌症相关死亡率。使用DO7（Dako）检测p53免疫反应性，使用K492（Dako）检测bcl-2免疫反应性。超过10%的细胞出现细胞质bcl-2或细胞核p53染色积聚的肿瘤被视为阳性。统计分析采用Pearson卡方检验、对数秩检验和Wilcoxon检验，以及Kaplan-Meier生存估计（显著性水平：p<0.05）。
11.8%（14/118）的肿瘤中发现p53阳性，50%（58/116）的肿瘤中发现bcl-2阳性，6.4%（7/109）的肿瘤中发现p53和bcl-2联合阳性。这些生物标志物的表达与TNM I、II、III和IV期分期之间无显著相关性（p53为p = 0.385；bcl-2为p = 0.461）。对于肿瘤复发，9.5%（2/21）的肿瘤中发现p53阳性，50%（11/22）的肿瘤中发现bcl-2阳性，5.2%（1/19）的肿瘤中发现p53和bcl-2联合阳性（分别为p = 0.714、p = 1.000和p = 0.960）。对于生存分析，p53阳性患者为57个月（45.0 - 68.0），bcl-2阳性患者为78个月（37.0 - 89.0），p53和bcl-2联合阳性患者为62个月（56.0 - 68.0）（p = 0.319）。对于癌症相关死亡率，8.3%（3/36）的p53阳性患者、47.2%（17/36）的bcl-2阳性患者和5.9%（2/36）的p53和bcl-2联合阳性患者死亡（分别为p = 0.432、p = 0.688和p = 0.907）。
未发现结直肠癌中p53和bcl-2的肿瘤表达与TNM分期、复发、生存及癌症相关死亡率之间存在相关性。
